Formulated for lymphomas and leukemia to manage malignant cell growth and support oncology care.
Mechanism of Action
Cyclophosphamide is converted in the liver to active metabolites that act as alkylating agents. These form cross-links between DNA strands, interfering with DNA replication and preventing cellular division in cancer cells.
Route of Administration
Oral
Onset Time
2–3 weeks
Duration
3–12 hours (half-life)
Contraindications
Severe bone marrow suppression, Pregnancy, Hypersensitivity to cyclophosphamide
Severe Adverse Events
Hemorrhagic cystitis, Myelosuppression, Secondary malignancy — requires immediate medical attention
Common Side Effects
Alopecia, Nausea, Vomiting
Uncommon Side Effects
Stomatitis, Anemia, Diarrhea
Drug Interactions
Alcohol, Warfarin, Digoxin, Allopurinol, Live Vaccines
Pregnancy Safety Warnings
FDA Category D: High risk of fetal toxicity. Breastfeeding: Discontinue nursing while taking this drug.
Age Restrictions
Safety and efficacy established in pediatric patients for oncology and nephrotic syndrome.
Information related to Cyclophosphamide is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
